Objective To evaluate the therapeutic efficacy of combination therapy comprised of plasma perfusion(PP),and plasma exchange(PE),and entecavir for treating patients with hepatitis B virus(HBV)-related acute-on-chronic liver failure(ACLF).Methods Seventy-six patients with HBV-ACLF were divided into two equal treatment groups: control,receiving the basic treatment of PE(time: 1.5-2.5 h,blood flow rate: 110-150 ml/min,plasma separation rate: 20-30 ml/min,replacement plasma volume: 2200-2800 ml) and entecavir(0.5 mg/d) for four weeks;combination therapy,receiving the basic treatment plus PP absorption.Serum levels of total bilirubin(TBil),prothrombin activity(PTA),and albumin(Alb) were measured before treatment,at the end of treatment,and at 72 h post-treatment.Results The total effective rate of the combination therapy group was significantly higher than that of the control group(62.9% vs.61.8%,P0.05).Serum TBil levels at the end of treatment and at 72 h post-treatment were significantly lower than those before treatment for both groups(P0.05),but the decrease in levels was significantly more extensive in the combination therapy group than in the control group(P0.05).Levels of PTA and Alb in the control groups were significantly higher at the end of treatment than before treatment(P0.05),and the levels were even more extensively decreased at 72 h post-treatment(P0.05).Compared with the pre-therapy levels,serum PTA and Alb in the combination therapy group were not different at the end of treatment or at 72 h post-treatment.Conclusion Adding PP to the basic therapy of PE and entecavir increases the efficacy for treating HBV-ACLF.